# Bone Biologics Corp: overview BBLG · Nasdaq · CIK 1419554 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/bblg.md) · [Financials](/companies/bblg/financials.md) · [Filings](/companies/bblg/filings.md) · [Insiders](/companies/bblg/insiders.md) Latest reported revenue: [$0](/filings/0001493152-21-020020.md) for Q2 FY2021, three months to 2021-06-30, from the 10-Q filed Aug 16, 2021 (XBRL us-gaap:Revenues, accession 0001493152-21-020020). ## Last eight quarters | Line item | Unit | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | not reported | [(1.92)](/filings/0001493152-26-023163.md) | [(1.33)](/filings/0001493152-26-038482.md) | [(0.37)](/filings/0001493152-26-048571.md) | not reported | [(0.43)](/filings/0001493152-26-023163.md) | [(0.43)](/filings/0001493152-26-038482.md) | [(0.17)](/filings/0001493152-26-048571.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. Derived values: 12-month figure less the 9-month figure. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Derived values: 12-month figure less the 9-month figure; 6-month figure less the 3-month figure; 9-month figure less the 6-month figure. ## Last five fiscal years | Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | | Revenue | $ | not reported | not reported | not reported | not reported | not reported | | Gross margin | % | not reported | not reported | not reported | not reported | not reported | | Operating margin | % | not reported | not reported | not reported | not reported | not reported | | Net margin | % | not reported | not reported | not reported | not reported | not reported | | Diluted EPS | $ per share | [(0.35)](/filings/0001493152-22-006850.md) | [(31.15)](/filings/0001493152-24-007432.md) | [(34.01)](/filings/0001493152-25-008383.md) | [(28.96)](/filings/0001493152-26-008564.md) | [(2.65)](/filings/0001493152-26-008564.md) | | Free cash flow | $ | not reported | not reported | not reported | not reported | not reported | - Revenue. XBRL not reported. - Gross margin (gross profit / revenue). XBRL not reported. - Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss. - Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss. - Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareBasicAndDiluted; Diluted EPS: us-gaap:EarningsPerShareDiluted. - Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities. Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing. ## Insider purchases and sales The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/bblg/insiders.md) None in coverage. ## Funds that report holding it From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md) | Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before | | --- | --- | ---: | ---: | --- | --- | | [CITADEL ADVISORS LLC](/funds/1423053.md) | 2026-06-30 | $32.7k | 23,879 | | New +23,879 | | [Tower Research Capital LLC (TRC)](/funds/1533421.md) | 2026-06-30 | $2.7k | 1,953 | | Reduced −2,173 | | [SBI Securities Co., Ltd.](/funds/1851815.md) | 2026-06-30 | $315 | 230 | | Unchanged | ## Recent filings [All 474 filings](/companies/bblg/filings.md) | Filed | Accepted | Form | What it is | Accession | | --- | --- | --- | --- | --- | | 2026-10-26 | 17:00 ET | [10-Q](/filings/0001493152-26-048571.md) | Quarterly report, period 2026-09-30 | 0001493152-26-048571 | | 2026-09-29 | 17:00 ET | [8-K](/filings/0001493152-26-044889.md) | 5.07 Shareholder vote results | 0001493152-26-044889 | | 2026-09-16 | 17:00 ET | [8-K](/filings/0001493152-26-042940.md) | 3.01 Delisting notice | 0001493152-26-042940 | | 2026-08-28 | 17:27 ET | [DEF 14A](/filings/0001493152-26-040640.md) | Proxy statement, period 2026-08-28 | 0001493152-26-040640 | | 2026-08-14 | 17:00 ET | [10-Q](/filings/0001493152-26-038482.md) | Quarterly report, period 2026-06-30 | 0001493152-26-038482 | | 2026-07-23 | 08:05 ET | [8-K](/filings/0001493152-26-034334.md) | 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001493152-26-034334 | | 2026-07-16 | 17:25 ET | [8-K](/filings/0001493152-26-033586.md) | 8.01 Other events | 0001493152-26-033586 | | 2026-07-09 | 16:30 ET | [8-K](/filings/0001493152-26-032694.md) | 1.01 Entry into a material agreement; 3.02 Unregistered sale of equity; 8.01 Other events; 9.01 Financial statements and exhibits | 0001493152-26-032694 | | 2026-07-02 | 08:00 ET | [DEF 14A](/filings/0001493152-26-031652.md) | Proxy statement, period 2026-07-02 | 0001493152-26-031652 | | 2026-05-14 | 17:00 ET | [10-Q](/filings/0001493152-26-023163.md) | Quarterly report, period 2026-03-31 | 0001493152-26-023163 | ## Latest annual report [Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001493152-26-008564.md), filed Mar 2, 2026. ## Forecast league Not in this season’s league. [This season’s league](/leagues.md) ## About the filer - CIK: 1419554 - Tickers: BBLG - Exchange: Nasdaq - SIC code: 3842 Orthopedic, Prosthetic & Surgical Appliances & Supplies - State of incorporation: DE - Filer category: Non-accelerated filer
Smaller reporting company Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 26, 2026, 17:12 ET. No prices; not investment advice.